Clinical Trial Update: Phase 2a Study of IW-9179 to Treat Functional Dyspepsia [Phase 2]

View source ↗

Summary

Ironwood’s Phase 2a study of IW-9179 for functional dyspepsia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Functional Dyspepsia
• Functional Gastrointestinal Disorders

Drugs mentioned

• IW-9179

Snippet

Sponsor: Ironwood Pharmaceuticals, Inc. | Conditions: Dyspepsia, Functional Gastrointestinal Disorders | Phase 2 | Status: TERMINATED